Eickhoff, M.K.; Dekkers, C.C.J.; Kramers, B.J.; Laverman, G.D.; Frimodt-Møller, M.; Jørgensen, N.R.; Faber, J.; Danser, A.H.J.; Gansevoort, R.T.; Rossing, P.;
et al. Effects of Dapagliflozin on Volume Status When Added to Renin–Angiotensin System Inhibitors. J. Clin. Med. 2019, 8, 779.
https://doi.org/10.3390/jcm8060779
AMA Style
Eickhoff MK, Dekkers CCJ, Kramers BJ, Laverman GD, Frimodt-Møller M, Jørgensen NR, Faber J, Danser AHJ, Gansevoort RT, Rossing P,
et al. Effects of Dapagliflozin on Volume Status When Added to Renin–Angiotensin System Inhibitors. Journal of Clinical Medicine. 2019; 8(6):779.
https://doi.org/10.3390/jcm8060779
Chicago/Turabian Style
Eickhoff, Mie K., Claire C. J. Dekkers, Bart J. Kramers, Gozewijn Dirk Laverman, Marie Frimodt-Møller, Niklas Rye Jørgensen, Jens Faber, A. H. Jan Danser, Ron T. Gansevoort, Peter Rossing,
and et al. 2019. "Effects of Dapagliflozin on Volume Status When Added to Renin–Angiotensin System Inhibitors" Journal of Clinical Medicine 8, no. 6: 779.
https://doi.org/10.3390/jcm8060779
APA Style
Eickhoff, M. K., Dekkers, C. C. J., Kramers, B. J., Laverman, G. D., Frimodt-Møller, M., Jørgensen, N. R., Faber, J., Danser, A. H. J., Gansevoort, R. T., Rossing, P., Persson, F., & Heerspink, H. J. L.
(2019). Effects of Dapagliflozin on Volume Status When Added to Renin–Angiotensin System Inhibitors. Journal of Clinical Medicine, 8(6), 779.
https://doi.org/10.3390/jcm8060779